Professor Ernest Choy

(he/him)

2026

• Martínez-Mateu, S. H. et al., 2026. Uncovering combination therapies for immune-mediated inflammatory diseases through systems biology analysis on longitudinal patient data. Cell Reports Medicine 103026. (10.1016/j.xcrm.2026.103026)
• Berthelsen, D. et al., 2026. Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinement. Seminars in Arthritis and Rheumatism 79 153026. (10.1016/j.semarthrit.2026.153026)
• Costa, D. O. et al. 2026. Interleukin-6 stimulates platelet 12-lipoxygenase to drive coagulation in inflammatory arthritis.. Journal of Lipid Research 67 (8) 101093. (10.1016/j.jlr.2026.101093)
• Lage-Hansen, P. R. et al., 2026. Understanding patient and physician global assessments in rheumatoid arthritis: A meta-epidemiological study of core outcome set performance. Seminars in Arthritis and Rheumatism 79 153023. (10.1016/j.semarthrit.2026.153023)
• Reginster, J. et al., 2026. Phenotypic factors and celecoxib efficacy in knee OA: A post‑hoc pooled analysis of two randomized, double‑blind, placebo‑controlled trials. Pain and Therapy (10.1007/s40122-026-00879-y)
• Pickles, T. et al. 2026. Patient global assessment in rheumatoid arthritis: general health and disease activity are not interchangeable [Letter to the Editor]. Rheumatology 65 (7) keag376. (10.1093/rheumatology/keag376)
• Khot, S. et al. 2026. The complexity of pain in inflammatory arthropathies beyond pain intensity and impact: An OMERACT initiative. Seminars in Arthritis and Rheumatism 78 152962. (10.1016/j.semarthrit.2026.152962)
• Sheppard, R. et al. 2026. Decision on optimal combinatorial therapies in immune-mediated inflammatory diseases using systems approaches (DocTIS): protocol for a single-arm, adaptive basket trial in rheumatoid and psoriatic arthritis. Rheumatology Advances in Practice 10 (2) rkag036. (10.1093/rap/rkag036)
• Bai, J. Q. A. et al., 2026. Dermatomyositis mortality by myositis‐specific autoantibodies: A systematic review and meta‐analysis [Letter]. Journal of the European Academy of Dermatology and Venereology jdv.70525. (10.1111/jdv.70525)
• Palmowski, A. et al., 2026. Changes in bone mineral density and fractures during 2 years of low-dose glucocorticoid treatment for rheumatoid arthritis: a systematic literature review and individual participant data meta-analysis. RMD Open: Rheumatic and Musculoskeletal Diseases 12 (2), pp.e006615. (10.1136/rmdopen-2025-006615)
• Pickles, T. , Davies, J. and Choy, E. 2026. Thoughts of people living with rheumatoid arthritis on a weekly rheumatoid arthritis disease activity monitoring tool [Abstract]. Rheumatology (United Kingdom) 65 (Supp_2) keag121.312. (10.1093/rheumatology/keag121.312)
• Matsuno, H. et al., 2026. Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised study. EULAR Rheumatology Open 2 , pp.155-165. (10.1016/j.ero.2025.12.010)
• Jiménez-Gracia, L. et al., 2026. Interpretable inflammation landscape of circulating immune cells. Nature Medicine 32 , pp.633-644. (10.1038/s41591-025-04126-3)
• Choy, E. H. et al. 2026. Understanding the immunopathophysiology of polymyalgia rheumatica: implications for treatment. Annals of the Rheumatic Diseases 85 (1), pp.6-21. (10.1016/j.ard.2025.09.005)
• Smolen, J. S. et al., 2026. Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial. RMD Open: Rheumatic and Musculoskeletal Diseases 12 e006094. (10.1136/rmdopen-2025-006094)
• Choy, E. et al. 2026. Different dosing regimens for chronic knee osteoarthritis (KOA) pain management: A pooled analysis on celecoxib. Aging Clinical and Experimental Research 38 (1) 55. (10.1007/s40520-025-03302-2)
• Derrac Soria, A. et al. 2026. IL-6 and IL-27 negatively regulate CRTAM-expressing CD4+ T-cells associated with lymphoid-driven synovitis. null (10.1101/2024.09.03.610972)
• Choy, E. et al. 2026. Clinical development programme of RGB-19 as a biosimilar to tocilizumab. Video Journal of Biomedicine 8 (1), pp.18-20. (10.1080/26315904.2026.2702116)

2025

• Pickles, T. et al. 2025. Assessing the content validity of patient reported outcome measure item pool for rheumatoid arthritis disease activity using cognitive interviews. Rheumatology 64 (12), pp.6176-6183. keaf421. (10.1093/rheumatology/keaf421)
• Geng, R. S. et al., 2025. Serum autoantibodies in dermatomyositis and systemic lupus erythematosus: a systematic review and meta-analysis [Letter]. Journal of Cutaneous Medicine and Surgery (10.1177/12034754251404473)
• Cupit, C. et al., 2025. Chronicity rhetoric in health and welfare systems inhibits patient recovery: a qualitative, ethnographic study of fibromyalgia care. Social Science & Medicine 382 118313. (10.1016/j.socscimed.2025.118313)
• Hasunuma, T. et al., 2025. Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover study. EULAR Rheumatology Open 1 (3), pp.282-290. (10.1016/j.ero.2025.08.006)
• Pickles, T. et al. 2025. Patient reported outcome measures for rheumatoid arthritis disease activity: Rasch measurement theory to identify items and domains. Rheumatology 64 (9), pp.4902-4912. (10.1093/rheumatology/keaf189)
• Avouac, J. , Kay, J. and Choy, E. 2025. Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: potentials and challenges.. Seminars in Arthritis and Rheumatism 73 152740. (10.1016/j.semarthrit.2025.152740)
• Smith, S. L. et al., 2025. Validity and contributions to pain from the central aspects of pain questionnaire in rheumatoid arthritis. PAIN Reports 10 (4) e1295. (10.1097/PR9.0000000000001295)
• Costa, D. O. et al. 2025. Circulating membrane aminophospholipids contribute to thrombotic risk in rheumatoid arthritis.. Journal of Lipid Research 66 (7) 100842. (10.1016/j.jlr.2025.100842)
• Mariette, X. et al., 2025. Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes. RMD Open: Rheumatic and Musculoskeletal Diseases 11 (1) e005033. (10.1136/rmdopen-2024-005033)
• Coates, L. C. et al., 2025. Enhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel. Rheumatology 64 (2), pp.561-573. (10.1093/rheumatology/keae172)
• Coyle, C. et al., 2025. How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology 64 (1), pp.242-251. (10.1093/rheumatology/kead679)
• Varley, M. et al. 2025. Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.. BMJ Open 15 (1) e084345. (10.1136/bmjopen-2024-084345)

2024

• Khot, S. , Tackley, G. and Choy, E. 2024. How to distinguish non-inflammatory from inflammatory pain in RA?. Current Rheumatology Reports 26 , pp.403-413. (10.1007/s11926-024-01159-4)
• Sternberg, C. N. et al., 2024. Final Results from SAUL, a single-arm international study of atezolizumab in unselected patients with pretreated locally advanced/metastatic urinary tract carcinoma. European Urology Focus 10 (6), pp.938-946. (10.1016/j.euf.2024.05.007)
• Watson, L. et al., 2024. An international multicentre analysis of current prescribing practices and shared decision-making in psoriatic arthritis. Rheumatology 63 (12), pp.3449-3456. (10.1093/rheumatology/kead621)
• Cooksey, R. et al. 2024. The pattern of anti-IL-6 versus non-anti-IL-6 biologic disease modifying anti-rheumatic drugs use in patients with rheumatoid arthritis in Wales, UK: a real-world study using electronic health records. Rheumatology Advances in Practice 9 (1) rkae140. (10.1093/rap/rkae140)
• Maxwell, L. J. et al., 2024. Defining domains: Developing consensus-based definitions for foundational domains in OMERACT core outcome sets. Seminars in Arthritis and Rheumatism 66 152423. (10.1016/j.semarthrit.2024.152423)
• Charles-Schoeman, C. et al., 2024. Impact of Upadacitinib on laboratory parameters and related adverse events in patients with RA: Integrated data up to 6.5 years. Rheumatology and Therapy 11 (1), pp.157-175. (10.1007/s40744-023-00624-3)
• Pickles, T. et al. 2024. Exploring the complexities of pain phenotypes: OMERACT 2023 chronic pain working group workshop. Seminars in Arthritis and Rheumatism 64 152342. (10.1016/j.semarthrit.2023.152342)
• Taylor, P. C. et al., 2024. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases. Rheumatology 63 (2), pp.298-308. (10.1093/rheumatology/kead448)
• Caporali, R. et al., 2024. Start RA treatment - Biologics or JAK-inhibitors?. Autoimmunity Reviews 23 (1) 103429. (10.1016/j.autrev.2023.103429)

2023

• Bukhari, M. and Choy, E. 2023. Exploring and addressing health inequalities in patients with a rheumatic disease: report of a roundtable discussion. Rheumatology 62 (12), pp.3782-3784. (10.1093/rheumatology/kead408)
• Rivellese, F. et al., 2023. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials. The Lancet Rheumatology 5 (11), pp.e648-e659. (10.1016/S2665-9913(23)00241-2)
• Charles-Schoeman, C. et al., 2023. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open 9 (4) e003392. (10.1136/rmdopen-2023-003392)
• Eccleston, C. et al., 2023. The establishment, maintenance, and adaptation of high- and low-impact chronic pain: a framework for biopsychosocial pain research. PAIN 164 (10), pp.2143-2147. (10.1097/j.pain.0000000000002951)
• Pickles, T. et al. 2023. Patient reported outcome measures for rheumatoid arthritis disease activity: using Rasch measurement theory and cognitive interviewing to achieve more meaningful measurement [Abstract]. Presented at: ACR Convergence 2023 San Diego 10-15 November 2023. Vol. 75.Vol. Supp 9. Wiley. (10.1002/art.42700)
• Choy, E. et al. 2023. Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab. Rheumatology 62 (7), pp.2386-2393. (10.1093/rheumatology/keac659)
• Das, D. and Choy, E. 2023. Non-inflammatory pain in inflammatory arthritis. Rheumatology 62 (7), pp.2360-2365. (10.1093/rheumatology/keac671)
• Fernandez-Nasarre, A. et al., 2023. Epidermal IL-33 drives inflammation in necroptosis-induced skin inflammation by recruiting TNF-producing immune cells.. [Online].bioRXiv: bioRXiv. (10.1101/2023.07.28.550963)
• Taylor, P. C. et al., 2023. A JAK inhibitor for treatment of rheumatoid arthritis: The Baricitinib Experience. Journal of Clinical Medicine 12 (13) 4527. (10.3390/jcm12134527)
• Huizinga, T. et al., 2023. Clinical efficacy of sarilumab versus upadacitinib over 12 weeks: an indirect treatment comparison. Rheumatology and Therapy 10 , pp.539-550. (10.1007/s40744-022-00521-1)
• Curtis, J. R. et al., 2023. Real-world Sarilumab use and rule testing to predict treatment response in patients with rheumatoid arthritis: findings from the RISE registry. Rheumatology and Therapy 10 (4), pp.1055-1072. (10.1007/s40744-023-00568-8)
• Pickles, T. et al. 2023. P035 Patient-reported outcome measures for rheumatoid arthritis disease activity: using Rasch measurement theory to achieve more meaningful measurement. Rheumatology 62 (Supp 2)(10.1093/rheumatology/kead104.076)
• Sebba, A. et al., 2023. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry. Clinical Rheumatology (10.1007/s10067-023-06588-7)
• Kennedy, J. et al., 2023. Predicting a diagnosis of ankylosing spondylitis using primary care health records–A machine learning approach. PLoS ONE 18 (3) e0279076. (10.1371/journal.pone.0279076)
• Clauw, D. J. et al., 2023. Hypothetical model ignores many important pathophysiologic mechanisms in fibromyalgia. Nature Reviews Rheumatology (10.1038/s41584-023-00951-3)
• Ghosh, N. et al., 2023. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: a scoping review by the OMERACT irAE working group. Seminars in Arthritis and Rheumatism 58 152110. (10.1016/j.semarthrit.2022.152110)
• Taylor, P. C. et al., 2023. Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease. BMC Medicine 21 (1) 55. (10.1186/s12916-023-02746-5)
• van der Woude, J. et al., 2023. P520 Thromboembolic and major adverse cardiovascular events among patients in the filgotinib clinical trial programme. Presented at: 18th Congress of ECCO Copenhagen Copenhagen 1-4 March 2023. Vol. 17.Vol. S1. Oxford University Press. , pp.i646-i649. (10.1093/ecco-jcc/jjac190.0650)
• Bamias, A. et al., 2023. New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer 11 e005977. (10.1136/jitc-2022-005977)
• Takala, R. , Ramji, D. P. and Choy, E. 2023. The beneficial effects of pine nuts and its major fatty acid, pinolenic acid, on inflammation and metabolic perturbations in inflammatory disorders. International Journal of Molecular Sciences 24 (2) 1171. (10.3390/ijms24021171)

2022

• Charles-Schoeman, C. et al., 2022. MACE et MTEV au cours du programme d?essais cliniques sur l?upadacitinib dans la polyarthrite rhumatoïde, le rhumatisme psoriasique et la spondylarthrite ankylosante. Revue du Rhumatisme 89 (Supple), pp.A204-A205. (10.1016/j.rhum.2022.10.309)
• Doebl, S. et al., 2022. Comparing the impact of symptoms and health care experiences of people who have and have not received a diagnosis of fibromyalgia: A cross‐sectional survey within the PACFiND study. Arthritis Care and Research 74 (11), pp.1894-1902. (10.1002/acr.24723)
• Williams, D. et al. 2022. Identities of women who have an autoimmune rheumatic disease [ARD] during pregnancy planning, pregnancy and early parenting: A qualitative study. PLOS ONE 17 (11) e0263910. (10.1371/journal.pone.0263910)
• Cooksey, R. and Choy, E. 2022. Exploring gender differences, medical history, and treatments used in patients with fibromyalgia in the UK using primary-care data: a retrospective, population-based, cohort study. The Lancet Rheumatology 4 (S1) S20. (10.1016/s2665-9913(22)00296-x)
• Humby, F. et al., 2022. Rituximab versus tocilizumab and b-cell status in tnf-alpha inadequate-responder rheumatoid arthritis patients: the r4-ra rct. Efficacy and Mechanism Evaluation 9 (7)(10.3310/gopl1729)
• Aleteha, D. et al., 2022. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.. Annals of the Rheumatic Diseases (10.1136/ard-2022-222784)
• Cooksey, R. et al. 2022. Real-world use of an etanercept biosimilar including selective versus automatic substitution in inflammatory arthritis patients: a UK-based electronic health records study. Rheumatology Advances in Practice 6 (2) rkac056. (10.1093/rap/rkac056)
• Galloway, J. et al., 2022. Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination.. Clinical and Experimental Rheumatology 40 (7), pp.1432-1441. (10.55563/clinexprheumatol/0jdyse)
• Cooksey, R. et al. 2022. Shielding reduced incidence of COVID-19 in patients with inflammatory arthritis but vulnerability is associated with increased mortality. Rheumatology 61 (SI2), pp.SI120-SI128. keac283. (10.1093/rheumatology/keac283)
• Goebel, A. et al., 2022. Research recommendations following the discovery of pain sensitizing IgG autoantibodies in fibromyalgia syndrome. Pain Medicine 23 (6), pp.1084-1094. pnab338. (10.1093/pm/pnab338)
• Pickles, T. et al. 2022. P089 Patient-reported outcome measures for rheumatoid arthritis disease activity: a systematic review following COSMIN guidelines. Presented at: British Society for Rheumatology Annual Conference 2022 Glasgow, Scotland 25-27 April 2022. Rheumatology Supplement 1. Vol. 61., pp.keac133.088. (10.1093/rheumatology/keac133.088)
• Takala, R. et al. 2022. Pinolenic acid exhibits Anti-inflammatory and Anti-atherogenic effects in Peripheral blood- derived Monocytes from patients with Rheumatoid Arthritis. Scientific Reports 12 8807. (10.1038/s41598-022-12763-8)
• Rivellese, F. et al., 2022. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 r4ra randomized trial. Nature Medicine 28 , pp.1256–1268. (10.1038/s41591-022-01789-0)
• Takala, R. et al. 2022. Anti-inflammatory and immunoregulatory effects of pinolenic acid in rheumatoid arthritis. Rheumatology 61 (3), pp.992-1004. (10.1093/rheumatology/keab467)
• Pickles, T. et al. 2022. Patient reported outcome measures for rheumatoid arthritis disease activity: a systematic review following COSMIN guidelines. RMD Open 8 (1) e002093. (10.1136/rmdopen-2021-002093)
• Guillo, L. et al., 2022. Herpes Zoster and vaccination strategies in inflammatory bowel diseases: a practical guide. Clinical Gastroenterology and Hepatology 20 (3), pp.481-490. (10.1016/j.cgh.2020.10.027)
• Holman, A. J. et al., 2022. Considering immuno-autonomics in stratifying successful treatment of rheumatoid arthritis with tumor necrosis factor inhibition: comment on Cohen et al. Rheumatol Ther 2021 June 19. Rheumatology and Therapy 9 , pp.305-307. (10.1007/s40744-021-00386-w)
• Nagy, G. et al., 2022. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases 81 (1), pp.20-33. (10.1136/annrheumdis-2021-220973)

2021

• Maxwell, L. J. et al., 2021. The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2. Seminars in Arthritis and Rheumatism 51 (6), pp.1320-1330. (10.1016/j.semarthrit.2021.08.011)
• Rehberg, M. et al., 2021. Identification of a rule to predict response to sarilumab in patients with rheumatoid arthritis using machine learning and clinical trial data. Rheumatology and Therapy 8 , pp.1661-1675. (10.1007/s40744-021-00361-5)
• Ceeraz, S. et al., 2021. Harnessing CD8+CD28− regulatory T cells as a tool to treat autoimmune disease. Cells 10 (11) 2973. (10.3390/cells10112973)
• Quartuccio, L. and Choy, E. H. 2021. Rheumatologists at a crossroads: blocking tumour necrosis factor or interleukin 6 in disease-modifying anti-rheumatic drug inadequate responder patients with rheumatoid arthritis. Rheumatology 60 (11), pp.4953-4955. keab425. (10.1093/rheumatology/keab425)
• Pedersen, M. B. et al., 2021. Biopsychosocial rehabilitation for inflammatory arthritis and osteoarthritis: A systematic review and meta?analysis of randomized trials. Arthritis Care and Research (10.1002/acr.24816)
• Fernández-Gutiérrez, F. et al., 2021. Mining primary care electronic health records for automatic disease phenotyping: a transparent machine learning framework. Diagnostics 11 (10) 1908. (10.3390/diagnostics11101908)
• Bedke, J. et al., 2021. Partial response and stable disease correlate with positive outcomes in Atezolizumab-treated patients with advanced urinary tract carcinoma. European Urology Focus 7 (5), pp.1084-0191. (10.1016/j.euf.2020.10.009)
• D'Amico, F. et al., 2021. Biobetters in patients with immune-mediated inflammatory disorders: an international Delphi consensus. Autoimmunity Reviews 20 (7) 102849. (10.1016/j.autrev.2021.102849)
• Davies, R. et al. 2021. The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis. Rheumatology 60 (6), pp.2852-2861. keaa725. (10.1093/rheumatology/keaa725)
• Cooksey, R. et al. 2021. Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK. Rheumatology Advances in Practice 5 (2) rkab042. (10.1093/rap/rkab042)
• Sarzi-Puttini, P. et al., 2021. Diagnostic and therapeutic care pathway for fibromyalgia. Clinical and Experimental Rheumatology 39 (3)(10.55563/clinexprheumatol/zcp5hz)
• Sarzi-Puttini, P. et al., 2021. Fibromyalgia position paper. Clinical and Experimental Rheumatology 39 (3 Supp), pp.186-193. (10.55563/clinexprheumatol/i19pig)
• Bamias, A. et al., 2021. SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy. ESMO Open 6 (3) 100152. (10.1016/j.esmoop.2021.100152)
• Xu, C. et al., 2021. Differential binding of sarilumab and tocilizumab to IL-6Rα and effects of receptor occupancy on clinical parameters. Journal of Clinical Pharmacology 61 (5), pp.714-724. (10.1002/jcph.1795)
• Pedley, R. et al., 2021. Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritis. Rheumatology Advances in Practice 5 (2) rkaa063. (10.1093/rap/rkaa063)
• Pope, J. E. and Choy, E. H. 2021. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Seminars in Arthritis and Rheumatism 51 (1), pp.219-229. (10.1016/j.semarthrit.2020.11.005)
• Simon, L. S. et al., 2021. The Jak/STAT pathway: A focus on pain in rheumatoid arthritis. Seminars in Arthritis and Rheumatism 51 (1), pp.278-284. (10.1016/j.semarthrit.2020.10.008)
• Choy, E. et al. 2021. Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study. BMC Rheumatology 5 (1) 3. (10.1186/s41927-020-00173-0)
• Kostine, M. et al., 2021. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Annals of the Rheumatic Diseases 80 (1), pp.36-48. (10.1136/annrheumdis-2020-217139)
• Nagy, G. et al., 2021. EULAR definition of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases 80 (1), pp.31-35. (10.1136/annrheumdis-2020-217344)
• Humby, F. et al., 2021. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet 397 (10271), pp.305-317. (10.1016/S0140-6736(20)32341-2)

2020

• Pitzalis, C. , Choy, E. H. S. and Buch, M. H. 2020. Transforming clinical trials in rheumatology: towards patient-centric precision medicine. Nature Reviews Rheumatology 16 (10), pp.590-599. (10.1038/s41584-020-0491-4)
• Loriot, Y. et al., 2020. Safety and efficacy of atezolizumab in patients with autoimmune disease: subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. European Journal of Cancer 138 , pp.202-211. (10.1016/j.ejca.2020.07.023)
• Leung, M. , Choy, E. H. and Lau, C. 2020. Cumulative patient-based disease activity monitoring in rheumatoid arthritis - predicts sustained remission, flare and treatment escalation. Seminars in Arthritis and Rheumatism 50 (4), pp.749-758. (10.1016/j.semarthrit.2020.03.010)
• Ho, K. Y. et al., 2020. Practice advisory on the appropriate use of NSAIDs in primary care. Journal of Pain Research 2020 (13), pp.1925-1939. (10.2147/JPR.S247781)
• Choy, E. H. et al. 2020. Translating IL-6 biology into effective treatments. Nature Reviews Rheumatology 16 , pp.335-345. (10.1038/s41584-020-0419-z)
• Thompson, C. et al. 2020. CD28− Cells are increased in early rheumatoid arthritis and are linked with cytomegalovirus status. Frontiers in Medicine 7 129. (10.3389/fmed.2020.00129)
• Winthrop, K. L. et al., 2020. Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib. Annals of the Rheumatic Diseases 79 , pp.669-671. (10.1136/annrheumdis-2019-216566)
• Monnet, E. et al., 2020. Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study. Annals of the Rheumatic Diseases 79 , pp.316-323. (10.1136/annrheumdis-2019-216487)
• Pell, B. et al. 2020. Using visual timelines in telephone interviews: Reflections and lessons learned from the STAR Family Study. International Journal of Qualitative Methods 19 , pp.1-11. (10.1177/1609406920913675)

2019

• Lliso-Ribera, G. et al., 2019. Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). Annals of the Rheumatic Diseases 78 (12), pp.1642-1652. (10.1136/annrheumdis-2019-215751)
• Choy, E. H. and Dures, E. 2019. Fatigue in rheumatoid arthritis. Rheumatology 58 (S5), pp.v1-v2. (10.1093/rheumatology/kez314)
• Choy, E. H. 2019. Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis. Rheumatology 58 (S5), pp.v51-v55. (10.1093/rheumatology/kez389)
• Demmler, J. C. et al., 2019. Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case-control comparison. BMJ Open 9 (11) e031365. (10.1136/bmjopen-2019-031365)
• Ramjeeawon, A. and Choy, E. 2019. Neuropathic-like pain in psoriatic arthritis: evidence of abnormal pain processing. Clinical Rheumatology 38 (11), pp.3153-3159. (10.1007/s10067-019-04656-5)
• Williams, D. et al. 2019. “Nobody knows, or seems to know how rheumatology and breastfeeding works”: Women's experiences of breastfeeding whilst managing a long-term limiting condition – A qualitative visual methods study. Midwifery 78 , pp.91-96. (10.1016/j.midw.2019.08.002)
• Hewlett, S. et al., 2019. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations. Health Technology Assessment 23 (57), pp.1. (10.3310/hta23570)
• Pickles, T. et al. 2019. Adaptive trial designs in rheumatology: Report from the OMERACT Special Interest Group. Journal of Rheumatology 46 (10), pp.1406-1408. jrheum.181054. (10.3899/jrheum.181054)
• Choy, E. H. 2019. Using biologics safely. Rheumatology 58 (9), pp.1515-1516. (10.1093/rheumatology/kez129)
• Lewis, M. J. et al., 2019. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Reports 28 (9), pp.2455-2470.e5. (10.1016/j.celrep.2019.07.091)
• Mease, P. et al., 2019. Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison. European Journal of Rheumatology 6 (3), pp.113-121. (10.5152/eurjrheum.2019.19057)
• Baerwald, C. and Choy, E. 2019. Generalised musculoskeletal problems. Best Practice & Research Clinical Rheumatology 33 (3) 101441. (10.1016/j.berh.2019.101441)
• Choy, E. et al. 2019. The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clinical and Experimental Rheumatology 37 (4), pp.694-407. CER11619.
• Choy, E. et al. 2019. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. Rheumatology 58 (6), pp.1056-1064. (10.1093/rheumatology/key393)
• Choy, E. H. 2019. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology 58 (6), pp.953-962. key339. (10.1093/rheumatology/key339)
• Tarp, S. et al., 2019. Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. Seminars in Arthritis and Rheumatism 48 (6), pp.958-966. (10.1016/j.semarthrit.2018.10.002)
• Humby, F. et al., 2019. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Annals of the Rheumatic Diseases 78 (6), pp.761-772. (10.1136/annrheumdis-2018-214539)
• Macfarlane, G. J. et al., 2019. AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). BMC Rheumatology 3 (1), pp.-. 19. (10.1186/s41927-019-0066-7)
• Isaacs, J. D. et al., 2019. Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study. Rheumatology Advances in Practice 3 (1), pp.-. (10.1093/rap/rkz010)
• Sternberg, C. N. et al., 2019. Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract. European Urology (10.1016/j.eururo.2019.03.015)
• Hewlett, S. et al., 2019. Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT). Annals of the Rheumatic Diseases 78 (4), pp.465-472. (10.1136/annrheumdis-2018-214469)
• Choy, E. et al. 2019. IL-6: To immunity and beyond. BMJ Considerations in Medicine 2 (1), pp.19-23. (10.1136/conmed-2018-000004)
• Jones, S. A. et al. 2019. Interleukin 6: the biology behind the therapy. Considerations in Medicine 2 (10.1136/conmed-2018-000005)
• Smolen, J. S. et al., 2019. Targeting IL-6: a review of data. BMJ Considerations in Medicine 2 (1), pp.12-18. (10.1136/conmed-2018-000003)
• Takeuchi, T. et al., 2019. Considering new lessons about the use of IL-6 inhibitors in arthritis. BMJ Considerations in Medicine 2 (1), pp.7-11. (10.1136/conmed-2018-000002)
• Choy, E. et al. 2019. The need for comparative data in spondyloarthritis. Arthritis Research and Therapy 21 (1) 32. (10.1186/s13075-019-1812-3)
• Choy, E. et al. 2019. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses. RMD Open 5 (1) e000798. (10.1136/rmdopen-2018-000798)
• Strand, V. et al., 2019. Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis. Journal of Comparative Effectiveness Research 8 (7), pp.497-510. (10.2217/cer-2018-0141)

2018

• Piguet, V. and Choy, E. 2018. Dermatomyositis: a slow path towards targeted therapies or will conventional therapies prevail?. British Journal of Dermatology 179 (6), pp.1233-1234. (10.1111/bjd.16230)
• Cooksey, R. et al., 2018. Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. Seminars in Arthritis and Rheumatism 48 (3), pp.367-373. (10.1016/j.semarthrit.2018.03.005)
• Thompson, C. , Piguet, V. and Choy, E. 2018. The pathogenesis of dermatomyositis. British Journal of Dermatology 179 (6), pp.1256-1262. (10.1111/bjd.15607)
• Jordan, L. A. et al. 2018. Inhibition of CCL3 abrogated precursor cell fusion and bone erosions in human osteoclast cultures and murine collagen-induced arthritis. Rheumatology 57 (11), pp.2042-2052. (10.1093/rheumatology/key196)
• Macfarlane, G. J. et al., 2018. Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. Rheumatology 57 (11), pp.1982-1990. key206. (10.1093/rheumatology/key206)
• Vollenhoven, R. et al., 2018. Evaluation of the short‐, mid‐, and long‐term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis. Arthritis and Rheumatology 71 (5), pp.685-695. (10.1002/art.40780)
• McInnes, I. B. et al., 2018. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. Journal of Comparative Effectiveness Research 7 (11), pp.1107-1123. (10.2217/cer-2018-0075)
• Just, S. A. et al., 2018. Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe. RMD Open 4 (2), pp.e000799. (10.1136/rmdopen-2018-000799)
• Pamfil, C. and Choy, E. 2018. Functional MRI in rheumatic disease with a focus on fibromyalgia. Clinical and Experimental Rheumatology 36 Sup (5), pp.82-85. 114.
• Phillips, R. et al. 2018. Identifying the unmet information and support needs of women with autoimmune rheumatic diseases during pregnancy planning, pregnancy and early parenting: mixed-methods study. BMC Rheumatology 2 21. (10.1186/s41927-018-0029-4)
• Pickles, T. et al. 2018. Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials. Rheumatology Advances in Practice 2 (2) rky045. (10.1093/rap/rky045)
• Dolton, G. et al. 2018. Optimized peptide-MHC multimer protocols for detection and isolation of autoimmune T-cells. Frontiers in Immunology 9 1378. (10.3389/fimmu.2018.01378)
• Phillips, R. et al. 2018. Reaching a consensus on research priorities for supporting women with autoimmune rheumatic diseases during pre-conception, pregnancy and early parenting: A Nominal Group Technique exercise with lay and professional stakeholders. Wellcome Open Research 3 75. (10.12688/wellcomeopenres.14658.1)
• O'Mahony, A. et al., 2018. Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate. Journal of Translational Medicine 16 156. (10.1186/s12967-018-1532-5)
• Nurmohamed, M. et al., 2018. The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease: a systematic literature review. Drug Safety 41 (5), pp.473-488. (10.1007/s40264-017-0628-9)
• Arnold, L. M. et al., 2018. An evidence-based review of pregabalin for the treatment of fibromyalgia. Current Medical Research and Opinion 34 (8), pp.1397-1409. (10.1080/03007995.2018.1450743)
• Choy, E. et al. 2018. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology 57 (3), pp.499-507. (10.1093/rheumatology/kex443)
• Sarzi-Puttini, P. et al., 2018. Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria?. Autoimmunity Reviews 17 (1), pp.33-35. (10.1016/j.autrev.2017.11.007)

2017

• Choy, E. H. S. and Calabrese, L. H. 2017. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rhuematology 57 (11), pp.1885-1895. (10.1093/rheumatology/kex391)
• Macfarlane, G. J. et al., 2017. EULAR recommendations for management of fibromyalgia. Annals of the Rheumatic Diseases 76 (12), pp.-. e54. (10.1136/annrheumdis-2017-211587)
• Choy, E. H. S. et al. 2017. Treatment of rheumatoid arthritis with anti-tumor necrosis factor or tocilizumab therapy as first biologic in a global comparative observational study. Arthritis Care & Research 69 (10), pp.1484-1494. (10.1002/acr.23303)
• Cohen, S. et al., 2017. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Annals of the Rheumatic Diseases 76 (10), pp.1679-1687. (10.1136/annrheumdis-2016-210459)
• Winthrop, K. L. et al., 2017. The safety and immunogenicity of live Zoster Vaccination in patients with rheumatoid arthritis before starting Tofacitinib: a randomized phase II trial. Arthritis & Rheumatology 69 (10), pp.1969-1977. (10.1002/art.40187)
• Orr, C. et al., 2017. Synovial tissue research: a state-of-the-art review. Nature Reviews Rheumatology 13 (8), pp.463-475. (10.1038/nrrheum.2017.115)
• Kosek, E. et al., 2017. Lower placebo responses after long-term exposure to fibromyalgia pain. Journal of Pain 18 (7), pp.835-843. (10.1016/j.jpain.2017.02.434)
• Sime, K. , Choy, E. and Williams, A. 2017. Alterations to adipose tissue morphology during inflammatory arthritis is indicative of vasculopathology in DBA/1 mice. Adipocyte 6 (2), pp.87-101. (10.1080/21623945.2017.1295174)
• Burmester, G. R. et al., 2017. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 76 , pp.1078-1085. (10.1136/annrheumdis-2016-210297)
• Kia, S. and Choy, E. 2017. Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. Biomedicines 5 (2) 20. (10.3390/biomedicines5020020)
• Choy, E. et al. 2017. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Rheumatology 56 (5), pp.689-697. (10.1093/rheumatology/kew271)
• Low, A. S. L. et al., 2017. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 76 (4), pp.654-660. (10.1136/annrheumdis-2016-209784)
• Macfarlane, G. J. et al., 2017. EULAR revised recommendations for the management of fibromyalgia. Annals of the Rheumatic Diseases 76 (2), pp.318-328. (10.1136/annrheumdis-2016-209724)
• Fleischmann, R. F. et al., 2017. Long-term maintenance of certolizumab pegol safety and efficacy, in combination with methotrexate and as monotherapy, in rheumatoid arthritis patients. Rheumatology and Therapy 4 (1), pp.57-69. (10.1007/s40744-017-0060-8)

2016

• Leung, A. M. H. et al., 2016. Defining criteria for rheumatoid arthritis patient-derived disease activity score that correspond to Disease Activity Score 28 and Clinical Disease Activity Index based disease states and response criteria. Rhuematology 55 (11), pp.1954-1958. (10.1093/rheumatology/kew279)
• Owen, E. , Choy, E. and Piguet, V. 2016. Juvenile dermatomyositis: new clinical trial evidence to underpin therapeutic shared decision making. British Journal of Dermatology 175 (4), pp.665-666. (10.1111/bjd.14917)
• Rawlings, C. , Davies, R. and Choy, E. 2016. Anti cytokine therapy in chronic inflammatory arthritis. Cytokine 86 , pp.92-99. (10.1016/j.cyto.2016.07.015)
• Taylor, A. M. et al. 2016. Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. Pain 157 (9), pp.1836-1850. (10.1097/j.pain.0000000000000577)
• Porter, D. et al., 2016. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet 388 (10041), pp.239-247. (10.1016/S0140-6736(16)00380-9)
• Choy, E. H. 2016. Current treatments to counter sleep dysfunction as a pathogenic stimulus of fibromyalgia. Pain Management 6 (4), pp.339. (10.2217/pmt-2016-0009)
• Almeida, C. et al., 2016. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database of Systematic Reviews (10.1002/14651858.CD008334.pub2)
• Tarp, S. et al., 2016. Defining the optimal biological monotherapy in rheumatoid arthritis: a systematic review and meta-analysis of randomised trials. Seminars in Arthritis and Rheumatism 46 (6), pp.699-708. (10.1016/j.semarthrit.2016.09.003)
• Zhou, S. et al., 2016. Defining disease phenotypes in primary care electronic health records by a machine learning approach: A case study in identifying rheumatoid arthritis. PLOS ONE 11 (5), pp.e0154515. (10.1371/journal.pone.0154515)
• Davies, R. et al. 2016. Serum Vascular Cell Adhesion Molecule 1 levels are associated with vascular Dysfunction and increased cardiovascular risk in an animal model and patients with Rheumatoid Arthritis. Rheumatology 55 (Supp 1), pp.54-54. O41. (10.1093/rheumatology/kew102.004)
• Bykerk, V. P. et al., 2016. Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. RMD Open 2 (1) e000225. (10.1136/rmdopen-2015-000225)
• Taylor, A. et al. 2016. Defining chronic pain reply. Journal of Rheumatology 43 (4), pp.826-827. (10.3899/jrheum.151456)
• Liu, X. et al. 2016. The biology behind interleukin-6 targeted interventions. Current Opinion in Rheumatology 28 (2), pp.152-160. (10.1097/BOR.0000000000000255)
• Marchettini, P. et al., 2016. Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?. European Journal of Pain 20 (3), pp.472-482. (10.1002/ejp.763)
• Arnold, L. M. , Gebke, K. B. and Choy, E. 2016. Fibromyalgia: management strategies for primary care providers. International Journal of Clinical Practice 70 (2), pp.99-112. (10.1111/ijcp.12757)
• Ravindran, V. and Choy, E. 2016. Modified-release prednisone in rheumatoid arthritis: Rationale for chronotherapy, mechanistic considerations, and clinical implications. Indian Journal of Rheumatology 11 (4), pp.216-221.

2015

• Phillips, K. et al., 2015. Harmonizing pain outcome measures: results of the Pre-OMERACT meeting on partnerships for consensus on patient-important pain outcome domains between the Cochrane Musculoskeletal Group and OMERACT. Journal of Rheumatology 42 (10), pp.1943-1946. 194386. (10.3899/jrheum.141386)
• Taylor, A. M. et al. 2015. Is chronic pain a disease in its own right? Discussions from a Pre-OMERACT 2014 Workshop on chronic pain. Journal of Rheumatology 42 (10), pp.1947-1953. (10.3899/jrheum.141328)
• Choy, E. et al. 2015. Treatment of Rheumatoid Arthritis with an anti-tumour necrosis factor agent or Tocilizumab as first biologic therapy: Action, a global comparative observational study. Rheumatology 55 (Supp 1), pp.101-102. (10.1093/rheumatology/kew144.023)
• Hewlett, S. et al., 2015. Protocol for a randomised controlled trial for Reducing Arthritis Fatigue by clinical Teams (RAFT) using cognitive-behavioural approaches. BMJ Open 5 (8) e009061. (10.1136/bmjopen-2015-009061)
• Giles, J. L. et al. 2015. Response to comment on 'Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis'. Journal of Immunology 195 (1), pp.4-4. (10.4049/jimmunol.1500968)
• Ibrahim, F. et al., 2015. Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rhuematology 54 (6), pp.1050-1055. (10.1093/rheumatology/keu442)
• Choy, E. H. S. 2015. The role of sleep in pain and fibromyalgia. Nature Reviews Rheumatology 11 (9), pp.513-520. (10.1038/nrrheum.2015.56)
• Collins, F. L. et al., 2015. Death Receptor 3 (TNFRSF25) Increases mineral apposition by osteoblasts and region specific new bone formation in the axial skeleton of male DBA/1 mice. Journal of Immunology Research 2015 , pp.-. 901679. (10.1155/2015/901679)
• Giles, J. et al. 2015. Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis. The Journal of Immunology 194 (7), pp.3029-3034. (10.4049/jimmunol.1402956)

2014

• Lipkovich, I. A. et al., 2014. Typology of patients with fibromyalgia: cluster analysis of duloxetine study patients. BMC Musculoskeletal Disorders 15 450. (10.1186/1471-2474-15-450)
• Giles, J. L. et al. 2014. Functional analysis of a complement polymorphism (rs17611) associated with Rheumatoid Arthritis. Immunology 143 (s2), pp.181-182. (10.1111/imm.12407)
• Baron, R. et al., 2014. Improving the primary care physicians' decision making for fibromyalgia in clinical practice: development and validation of the Fibromyalgia Detection (FibroDetect®) screening tool. Health and Quality of Life Outcomes 12 128. (10.1186/s12955-014-0128-x)
• Lie, E. et al., 2014. Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study. Annals of the Rheumatic Diseases 73 , pp.1781. (10.1136/annrheumdis-2013-203496)
• Kirwan, J. R. et al., 2014. Updating the OMERACT filter: implications for patient-reported outcomes. Journal of Rheumatology 41 (5), pp.1011-1015. (10.3899/jrheum.131312)
• Bykerk, V. P. et al., 2014. Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA Flare Workshop. Journal of Rheumatology 41 (4), pp.799-809. (10.3899/jrheum.131252)
• Davies, R. and Choy, E. 2014. Clinical experience of IL-6 blockade in rheumatic diseases: implications on IL-6 biology and disease pathogenesis. Seminars in Immunology 26 (1), pp.97-104. (10.1016/j.smim.2013.12.002)
• Jensen, K. B. et al., 2014. Segregating the cerebral mechanisms of antidepressants and placebo in fibromyalgia. The Journal of Pain 15 (12), pp.1328-1337. (10.1016/j.jpain.2014.09.011)
• Kirwan, J. R. et al., 2014. Updating the OMERACT filter: core areas as a basis for defining core outcome sets. Journal of Rheumatology 41 (5), pp.994-999. (10.3899/jrheum.131309)
• Rawlings, C. and Choy, E. 2014. The future of biological agents in the treatment of rheumatoid arthritis. International Journal of Clinical Rheumatology 9 (5), pp.475-486. (10.2217/ijr.14.32)
• Tugwell, P. et al., 2014. Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity. Journal of Rheumatology 41 (5), pp.1000-1004. (10.3899/jrheum.131310)

2013

• van der Maas, A. et al., 2013. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Annals of the Rheumatic Diseases 72 (11), pp.1800-1805. (10.1136/annrheumdis-2012-202281)
• Choy, E. H. et al. 2013. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials. Arthritis Research and Therapy 15 (5) R132. (10.1186/ar4312)
• Smolen, J. et al., 2013. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases 72 (4), pp.482-492. (10.1136/annrheumdis-2012-202469)
• Bari, S. F. and Choy, E. H. S. 2013. Outcome measures in rheumatoid arthritis. Indian Journal of Rheumatology 8 (SUPPL1), pp.S31-S35. (10.1016/j.injr.2013.11.011)
• Ceeraz, S. et al., 2013. Defective CD8+CD28?regulatory T cell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy. Clinical and Experimental Immunology 174 (1), pp.18-26. (10.1111/cei.12161)
• Choy, E. H. S. , Kavanaugh, A. and Jones, S. A. 2013. The problem of choice: current biologic agents and future prospects in RA [review]. Nature Reviews Rheumatology 9 (3), pp.154-163. (10.1038/nrrheum.2013.8)
• Gullick, N. et al., 2013. Enhanced and persistent levels of IL-17+CD4+ T cells and serum IL-17 in patients with early inflammatory arthritis. Clinical and Experimental Immunology 174 (2), pp.292-301. (10.1111/cei.12167)
• Jensen, K. B. et al., 2013. Overlapping structural and functional brain changes in patients with long-term exposure to fibromyalgia pain. Arthritis & Rheumatism 65 (12), pp.3293-3303. (10.1002/art.38170)
• Petzke, F. et al., 2013. Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia. Scandinavian Journal of Pain 4 (2), pp.65-74. (10.1016/j.sjpain.2012.10.002)

2012

• Collins, F. et al. 2012. TNF-like protein 1A/death receptor 3 pathway regulates osteoclastogenesis and is associated with erosive disease in rheumatoid arthritis. Arthritis and Rheumatism 64 (10), pp.S768-S768.
• Spaeth, M. et al., 2012. Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: Results of an international phase 3 trial. Annals of the Rheumatic Diseases 71 (6), pp.935-942. (10.1136/annrheumdis-2011-200418)

2011

• Choy, E. H. S. et al. 2011. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Seminars in Arthritis and Rheumatism 41 (3), pp.335-345.e6. (10.1016/j.semarthrit.2011.06.003)
• Paringe, V. et al. 2011. Compromised expression of the complement membrane inhibitor CD59a propagates age-related joint degeneration in mice [Poster Abstract]. Arthritis and Rheumatism 63 (s10), pp.S947-S947. (10.1002/art.33310)
• Smale, S. et al. 2011. Inhibiting IL-6 trans-signalling with soluble gp130Fc potently reduces the incidence and severity of collagen-induced experimental arthritis [Abstract]. Arthritis and Rheumatism 63 (s10), pp.S446-S447.

2010

• Jensen, K. B. et al., 2010. Anxiety and depressive symptoms in fibromyalgia are related to poor perception of health but not to pain sensitivity or cerebral processing of pain. Arthritis & Rheumatism 62 (11), pp.3488-3495. (10.1002/art.27649)

2008

• Choy, E. H. S. et al. 2008. Development and validation of a patient-based disease activity score in rheumatoid arthritis that can be used in clinical trials and routine practice. Arthritis Care and Research 59 (2), pp.192-199. (10.1002/art.23342)
• Choy, E. H. S. et al. 2008. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Annals of the Rheumatic Diseases 67 (5), pp.656-663. (10.1136/ard.2007.076299)
• Ravindran, V. , Scott, D. L. and Choy, E. H. S. 2008. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Annals of the Rheumatic Diseases 67 (6), pp.855-859. (10.1136/ard.2007.072652)